Shalini Sharp Buys Shares of ONC

Shalini Sharp acquired 18,980 shares of ONC, highlighting insider activity.

Key Points

  • On June 11, 2026, Shalini Sharp acquired 18,980 shares of ONC, reflecting active insider trading.
  • ONC shares traded at $264.48 with analysts maintaining positive outlooks and setting high price targets.
  • Other insiders, including Xiaodong Wang and Henry Lee, also bought significant shares on the same day.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Shalini Sharp, an insider at ONC, purchased 18,980 shares of the company on June 11, 2026. The transaction was executed without a predetermined plan, reflecting a notable insider activity as ONC shares were priced at $264.48.

Insider Buying and Selling at BeOne Medicines AG

The insider buying spree at ONC was not limited to Shalini Sharp. Xiaodong Wang acquired 193,492 shares, and Henry Lee, the Senior Vice President and General Counsel, purchased 45,071 shares. Additionally, Xiaodong Wang made another buy of 99,892 shares, and Charles Lazelle Sawyers bought 18,980 shares on the same day. These transactions were all executed at no cost, suggesting a distribution of shares rather than a market purchase.

Other Institutional Activity in ONC

Institutional investors have also been active in ONC. Baker Bros. Advisors LP maintained its position with 8,799,053 shares valued at approximately $2.61 billion. Primecap Management Co/CA/ slightly reduced its holdings by 5,400 shares, ending with 4,975,181 shares worth about $1.48 billion. Capital International Investors significantly cut back, shedding 955,140 shares to hold 4,158,726 shares valued at $1.23 billion. FMR LLC also reduced its stake by 299,017 shares, bringing its total to 3,693,610 shares, valued at $1.10 billion. Meanwhile, Citadel Advisors LLC nearly doubled its position, adding 516,719 shares to reach a total of 1,050,236 shares, valued at approximately $306.6 million.

Analysts Set New Price Targets

Analysts have been active in updating their outlooks for ONC. On June 2, 2026, RBC Capital maintained its "buy" rating with a price target of $436. On May 15, 2026, Leerink Partners also kept a "buy" rating, setting a target of $367. Guggenheim and Barclays both maintained "buy" ratings on May 7, 2026, with targets of $420 and $409, respectively. Truist Securities reiterated a "buy" rating with a target of $413 on the same day. Wells Fargo initiated coverage with a "buy" rating and a $400 target on May 4, 2026.

Bottom Line

The insider purchases at ONC, led by Shalini Sharp and other executives, suggest confidence in the company's future. Investors often track insider transactions for potential insights into a company's prospects. While these trades provide valuable context, they are backward-looking and do not guarantee future performance. Analyst ratings and institutional activity further enrich the narrative around ONC, offering a comprehensive view of market sentiment.

Get BeOne Medicines AG alerts

New 13F filings, insider trades, and analyst moves on $ONC, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.